Journal
CLINICAL CANCER RESEARCH
Volume 17, Issue 16, Pages 5233-5238Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-3402
Keywords
-
Categories
Funding
- Prostate Cancer Foundation
- NIH, National Cancer Institute
- Center for Cancer Research
- NIH [R01 CA127153, 1P50CA58236-15, CA143083, CA78378, 5P01CA089021-10, 5P50CA090381-09]
- Patrick C. Walsh Fund
- OneInSix Foundation
- Leukemia & Lymphoma Society
- Melanoma Research Alliance
- Alliance for Cancer Gene Therapy
- Research Foundation for the Treatment of Ovarian Cancer
- Department of Defense
Ask authors/readers for more resources
The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U. S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies. Clin Cancer Res; 17(16); 5233-8. (C)2011 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available